MM
BIVV

Mason Morfit’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Mason Morfit’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,270,619
Closed -$72.5M – 16
2017
Q3 		$72.5M Sell
1,270,619
-5,893,273
-82% -$345M 0.73% 14
2017
Q2 		$431M Sell
7,163,892
-1,313,000
-15% -$74.8M 3.85% 10
2017
Q1 		$462M Buy
+8,476,892
New +$418M 3.87% 8

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Mason Morfit's BIVV Position: Q4 2017 in Review

Mason Morfit sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 1,270,619 shares — an estimated $72.5M sold.

Mason Morfit first reported a position in BIVV in Q1 2017 and held it in 3 quarters. The position peaked at $462M in Q1 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Mason Morfit reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Mason Morfit sold 1,270,619 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $72.5M.
  • Mason Morfit first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Mason Morfit's Bioverativ Inc. Common Stock position peaked at $462M in Q1 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on ValueAct Holdings's 13F filing for Q4 2017, filed 15 Feb 2018.